The Journal of Urology
Volume 178, Issue 3, Supplement , Pages S5-S8 , September 2007

Innovations and Challenges in Prostate Cancer: Summary Statement for the 6th Cambridge Conference

  • Philip W. Kantoff

      Affiliations

    • Lank Center for Genitourinary Oncology, Boston, Massachusetts
    • ,
  • Tomasz M. Beer

      Affiliations

    • Division of Hematology and Medical Oncology and Oregon Health and Science University Cancer Institute, Oregon Health and Science University, Portland, Oregon
    • ,
  • Anthony V. D’Amico

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
    • Department of Radiation Oncology, Brigham and Women’s Hospital, Boston, Massachusetts
    • ,
  • Robert S. DiPaola

      Affiliations

    • Cancer Institute of New Jersey, New Brunswick, New Jersey
    • ,
  • Mario A. Eisenberger

      Affiliations

    • Departments of Oncology and Urology, Johns Hopkins University, Baltimore, Maryland
    • ,
  • Maha H.A. Hussain

      Affiliations

    • Department of Internal Medicine (Division of Hematology and Oncology), University of Michigan, Ann Arbor, Michigan
    • ,
  • William Kevin Kelly

      Affiliations

    • Department of Medical Oncology, Yale University, New Haven, Connecticut
    • ,
  • Paul Mathew

      Affiliations

    • M. D. Anderson Cancer Center, Houston
    • ,
  • Michael J. Morris

      Affiliations

    • Genitourinary Oncology Service, Department of Medicine and Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center and Department of Medicine, Joan and Sanford E. Weill College of Medicine of Cornell University, New York, New York
    • ,
  • Charles J. Ryan

      Affiliations

    • Department of Medicine, University of California-San Francisco, San Francisco, California
    • University of California-San Francisco Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California
    • ,
  • Howard M. Sandler

      Affiliations

    • Department of Radiation Oncology and Urology, University of Michigan, Ann Arbor, Michigan
    • ,
  • Ian M. Thompson

      Affiliations

    • Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas
    • ,
  • Peter R. Carroll

      Affiliations

    • Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California-San Francisco, San Francisco, California

References 

  1. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215
  2. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of inasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98:1128
  3. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977
  4. Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20:557
  5. D’Amico AV. Combined-modality staging in predicting prostate-specific antigen outcome after definitive local therapy for men with clinically localized prostate cancer. In: Prostate Cancer: Principles and Practice. Philadelphia: Lippincott Williams & Wilkins; 2002;p. 254–268
  6. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141
  7. Eisenberger MA, Partin AW, Pound C, Roostelaar CV, Epstein J, Walsh P. Natural history of progression in patients with biochemical (PSA) relapse following radical prostatectomy: update. Proc Am Soc Clin Oncol. 2003;22:1527
  8. Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol. 2005;23:6556
  9. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458
  10. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002;20:3072
  11. Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, et al. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer. 2003;98:1603

PII: S0022-5347(07)00825-7

doi: 10.1016/j.juro.2007.03.137

The Journal of Urology
Volume 178, Issue 3, Supplement , Pages S5-S8 , September 2007

Article Tools